We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Editas (EDIT) Down 19.5% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Editas Medicine (EDIT - Free Report) . Shares have lost about 19.5% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Editas due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Editas' Loss Narrows in Q2, Revenues Trump Estimates
Editas incurred a loss of 78 cents per share in the second quarter of 2022, narrower than the Zacks Consensus Estimate of a loss of 84 cents. The company had reported a loss of 81 cents per share in the year-ago quarter.
Collaboration, and other research and development revenues, comprising the company’s top line, came in at $6.4 million in the reported quarter compared with $0.4 million in the year-ago quarter. Revenues in the second quarter grew significantly, owing to additional programs licensed by Bristol Myers Squibb. The top line also beat the Zacks Consensus Estimate of $5 million.
Quarter in Detail
In the second quarter of 2022, research and development expenses were $43.7 million, up 29.3% from the year-ago figure, owing to higher expenses related to clinical studies.
General and administrative expenses decreased 23.1% to $16.9 million, owing to performance awards granted in 2021, while no similar expenses were recorded in the second quarter of 2022.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended upward during the past month.
VGM Scores
Currently, Editas has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions has been net zero. Notably, Editas has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Editas (EDIT) Down 19.5% Since Last Earnings Report?
It has been about a month since the last earnings report for Editas Medicine (EDIT - Free Report) . Shares have lost about 19.5% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Editas due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Editas' Loss Narrows in Q2, Revenues Trump Estimates
Editas incurred a loss of 78 cents per share in the second quarter of 2022, narrower than the Zacks Consensus Estimate of a loss of 84 cents. The company had reported a loss of 81 cents per share in the year-ago quarter.
Collaboration, and other research and development revenues, comprising the company’s top line, came in at $6.4 million in the reported quarter compared with $0.4 million in the year-ago quarter. Revenues in the second quarter grew significantly, owing to additional programs licensed by Bristol Myers Squibb. The top line also beat the Zacks Consensus Estimate of $5 million.
Quarter in Detail
In the second quarter of 2022, research and development expenses were $43.7 million, up 29.3% from the year-ago figure, owing to higher expenses related to clinical studies.
General and administrative expenses decreased 23.1% to $16.9 million, owing to performance awards granted in 2021, while no similar expenses were recorded in the second quarter of 2022.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended upward during the past month.
VGM Scores
Currently, Editas has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions has been net zero. Notably, Editas has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.